| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2024―Apr―25 |
Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind phase I study in healthy subjects |
Cheng Sun, Hao Liu, Ziwei Ouyang, Jie Ding, Qin Zhang, Hongjie Ma, et al. (+5) Dandan Xu, Qian Zhang, Renpeng Zhou, Mingming Yang, Wei Hu |
| 2 |
[GO] |
2023―Jun―26 |
Long COVID [post-acute sequelae of coronavirus disease 2019]: Experimental drugs for cardiopulmonary complications |
Fabio Angeli, Paolo Verdecchia, Gianpaolo Reboldi |
| 3 |
[GO] |
2022―Sep―01 |
Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics |
Denise Battaglini, Fernanda Cruz, Chiara Robba, Paolo Pelosi, Patricia R.M. Rocco |
| 4 |
[GO] |
2022―Mar―16 |
Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: A critical discussion of recent publications |
Jose Garrido-Mesa, Kate Adams, Julio Galvez, Natividad Garrido-Mesa |
| 5 |
[GO] |
2022―Feb―15 |
Monoclonal antibody therapies in the management of SARS-CoV-2 infection |
Enrique Miguez-Rey, Dasom Choi, Seungmin Kim, Sangwook Yoon, Oana Săndulescu |
| 6 |
[GO] |
2021―Jun―30 |
Low-dose aspirin for early COVID-19: Does the early bird catch the worm? |
John G. Rizk, Carl J. Lavie, Ajay Gupta |
| 7 |
[GO] |
2021―Mar―15 |
The Time to Offer Treatments for COVID-19 |
Binh T. Ngo, Paul Marik, Pierre Kory, Leland Shapiro, Raphael Thomadsen, Jose Iglesias, et al. (+31) Stephen Ditmore, Marc Rendell, Joseph Varon, Michael Dubé, Neha Nanda, Gino In, Daniel Arkfeld, Preet Chaudhary, Vito M. Campese, Diana L. Hanna, David E. Sawcer, Glenn Ehresmann, David Peng, Miroslaw Smogorewski, April Armstrong, Rajkumar Dasgupta, Fred Sattler, Denise Brennan-Rieder, Cristina Mussini, Oriol Mitja, Vicente Soriano, Nicolas Peschanski, Gilles Hayem, Marco Confalonieri, Maria Carmela Piccirillo, Antonio Lobo-Ferreira, Iraldo Bello Rivero, Mika Turkia, Eivind H. Vingevoll, Daniel Griffin, Ivan FN Hung |
| 8 |
[GO] |
2020―Dec―23 |
The design and analysis of non-randomized studies: A case study of off-label use of hydroxychloroquine in the COVID-19 pandemic |
Derek Shyr, Yu Shyr |
| 9 |
[GO] |
2020―Oct―23 |
Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease |
Zeyun Zhou, Christina C. Price |
| 10 |
[GO] |
2020―Sep―08 |
Remdesivir, a remedy or a ripple in severe COVID-19? |
Sheila A Doggrell |
| 11 |
[GO] |
2020―Jun―01 |
Does lopinavir measure up in the treatment of Covid-19? |
Sheila A Doggrell |
| 12 |
[GO] |
2020―May―18 |
Emerging therapies for COVID-19 pneumonia |
Denise Battaglini, Chiara Robba, Lorenzo Ball, Fernanda Ferreira Cruz, Pedro Leme Silva, Paolo Pelosi, Patricia Rieken Macedo Rocco |
|
